StockNews.com cut shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) from a buy rating to a hold rating in a research report sent to investors on Thursday.
Separately, HC Wainwright dropped their price target on TRACON Pharmaceuticals from $120.00 to $60.00 and set a buy rating for the company in a research note on Wednesday, April 3rd.
Get Our Latest Research Report on TCON
TRACON Pharmaceuticals Trading Up 11.9 %
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last released its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.13). The company had revenue of $0.10 million for the quarter. During the same period last year, the business posted ($7.20) earnings per share. On average, analysts predict that TRACON Pharmaceuticals will post -4 EPS for the current year.
TRACON Pharmaceuticals Announces Dividend
The company also recently announced a dividend, which will be paid on Monday, July 8th. Stockholders of record on Friday, June 28th will be given a dividend of $0.045 per share. The ex-dividend date of this dividend is Thursday, June 27th. This represents a dividend yield of 40.3%.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Further Reading
- Five stocks we like better than TRACON Pharmaceuticals
- How to Calculate Inflation Rate
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Bank Stocks – Best Bank Stocks to Invest In
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Most Volatile Stocks, What Investors Need to Know
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.